Aptus Pharma Ltd (544529)
Latest quarterly results (H2 FY26)
In its latest reported quarter, H2 FY26, Aptus Pharma's revenue was ₹32.2 Cr (+117.6% year on year, +123.9% on the previous half-year), and net profit ₹2.9 Cr (+60.3% year on year); the operating margin was 14.0%.
| H2 FY26 (₹ Cr) | Value | YoY vs H2 FY25 | vs prev. half |
|---|---|---|---|
| Revenue | ₹32.2 | +117.6% | +123.9% |
| Operating profit | ₹4.5 | +56.8% | +53.6% |
| Net profit | ₹2.9 | +60.3% | +64.0% |
| EPS (₹) | 1.67 | — | +63.7% |
| Operating margin | 14.0% | — | — |
No EPS growth against H2 FY25: 3:2 bonus in May 2026.
📢 Recent Corporate Announcements
Aptus Pharma's Board has approved a proposal to raise ₹44.88 crore via a preferential issue of equity shares, subject to shareholder approval at the AGM on September 14, 2026. The company intends to allocate ₹25 crore towards capital expenditure to establish its own manufacturing facility, targeting ~20% in-house production to transition from a purely marketing-led model. The remaining proceeds include ₹10 crore for working capital and ₹9.88 crore for general corporate purposes and debt reduction over a 36-month period. Relative to its existing scale, the fundraise represents ~195% of net worth (₹23 crore) and ~63% of TTM revenue (₹71 crore).
- Board approved ₹44.88 crore fundraise via preferential issue to identified investors
- ₹25 crore earmarked for capex including land, plant structure, storage, and vehicles
- ₹10 crore allocated to working capital and ₹9.88 crore to general corporate purposes/debt reduction
- Company aims to produce ~20% of product requirements via in-house manufacturing
- AGM for shareholder approval scheduled for September 14, 2026; deployment planned within 36 months
Aptus Pharma Ltd released its investor presentation detailing FY26 financial performance and strategic roadmap. FY26 revenue from operations grew 89.7% YoY to Rs 46.57 crore compared to Rs 24.56 crore in FY25, with net profit rising 49.0% to Rs 4.62 crore. The company outlined strategic goals including achieving 20% in-house manufacturing by March 2028, expanding exports across Asia, Africa, and Latin America by March 2028, and reaching a Pan-India distribution presence by March 2029.
- FY26 revenue from operations increased by 89.7% YoY to Rs 46.57 crore from Rs 24.56 crore in FY25
- FY26 PAT grew 49.0% YoY to Rs 4.62 crore with a net profit margin of 9.92%
- EBITDA for FY26 stood at Rs 7.45 crore (16.00% margin) vs Rs 4.85 crore (19.70% margin) in FY25
- H2 FY26 revenue reached Rs 32.20 crore, marking a 117% increase over H2 FY25 (Rs 14.80 crore)
- Targets 20% own manufacturing capacity and global expansion by March 2028, followed by Pan-India footprint by March 2029
Aptus Pharma Limited submitted its Annual Report for FY 2025-26 and scheduled its 16th Annual General Meeting for September 14, 2026. In FY26, revenue from operations grew 89.65% year-on-year to ₹46.57 crore (₹4,657.46 lakh), while Profit After Tax rose 49.05% to ₹4.62 crore (₹461.99 lakh). The product basket expanded from 194 to over 250 products during the year. Additionally, the company allotted 1,02,90,000 bonus shares in a 3:1 ratio post year-end following shareholder approval in April 2026.
- FY26 revenue from operations increased 89.65% YoY to ₹4,657.46 lakh vs ₹2,455.77 lakh in FY25
- FY26 Profit After Tax grew 49.05% YoY to ₹461.99 lakh vs ₹309.96 lakh in FY25
- Product portfolio expanded to over 250 products as of March 31, 2026, up from 194 in FY25
- Completed a 3:1 bonus issue post year-end, allotting 1,02,90,000 equity shares
- 16th Annual General Meeting scheduled for September 14, 2026 via Video Conferencing
Aptus Pharma Limited has issued a notice for its 16th Annual General Meeting scheduled on September 14, 2026, seeking shareholder approval for a preferential issue of ₹44.88 Cr. The company proposes to allot 16,02,870 equity shares of face value ₹10 at an issue price of ₹280 per share (including a ₹270 premium) for cash consideration. This capital raise represents approximately 63% of TTM revenue (₹71 Cr) and nearly double its current net worth (₹23 Cr), significantly boosting the company's balance sheet for future growth.
- Proposed preferential issue of ₹44,88,03,600 (₹44.88 Cr) consisting of cash
- Allotment of 16,02,870 equity shares of face value ₹10 at an issue price of ₹280 per share
- Issue price includes a premium of ₹270 per equity share
- AGM scheduled for September 14, 2026, with remote e-voting from September 11 to September 13, 2026
- Allottees include public individuals, corporates, and select promoter group members
Aptus Pharma Limited's Board has approved a preferential issue of up to 16,02,870 equity shares of face value ₹10 each at an issue price of ₹280 per share, aggregating to approximately ₹44.88 Crores. The issue is proposed to 190 allottees, and the relevant date for pricing was determined as August 14, 2026. The proposed fundraise is sizable relative to the company's financial profile, representing ~63% of TTM revenue (₹71 Cr) and ~195% of net worth (₹23 Cr). Shareholder approval will be sought at the 16th Annual General Meeting scheduled for September 14, 2026.
- Preferential issue of 16,02,870 equity shares approved at ₹280 per share (face value ₹10)
- Total capital to be raised is approximately ₹44.88 Crores across 190 allottees
- Fundraise represents ~195% of current Net Worth (₹23 Cr) and ~63% of TTM Revenue (₹71 Cr)
- Valuation report taken on record with relevant date set as August 14, 2026
- 16th Annual General Meeting convened for Monday, September 14, 2026
Aptus Pharma has scheduled a board meeting for August 17, 2026, to determine the issue price for a preferential allotment of 16,10,100 equity shares. The relevant date for pricing calculation is set as August 14, 2026, in accordance with SEBI regulations. This fundraise follows a strong financial period where the company recorded TTM revenue of Rs 71 Cr and a healthy ROCE of 30%. The board will also finalize the notice for the 16th Annual General Meeting (AGM) to be held on September 14, 2026.
- Board meeting scheduled for August 17, 2026, to approve the valuation report and issue price.
- Proposed issuance of 16,10,100 equity shares on a preferential basis.
- Relevant date for determining the issue price is fixed as August 14, 2026.
- 16th Annual General Meeting (AGM) convened for September 14, 2026, via video conferencing.
- Trading window for designated persons closed from August 12, 2026, until 48 hours post-meeting.
Aptus Pharma Ltd has issued a clarification regarding its board meeting held on August 8, 2026, which originally approved a preferential issue of shares. The company corrected the meeting venue from the registered office to the Head Office in Rajkot and renamed 'Annexure 1' to 'Annexure A'. The management confirmed that these are purely typographical errors and do not change the substance or outcome of the resolutions passed. This administrative update follows a fiscal year (FY26) where the company reported revenue of Rs 46.57 Cr and a net profit of Rs 4.62 Cr.
- Clarification issued on August 10, 2026, for the board meeting held on August 8, 2026.
- Meeting venue corrected to Head Office at RK Trade Tower, Rajkot, Gujarat.
- Annexure title corrected from 'Annexure 1' to 'Annexure A' regarding the preferential issue.
- Company confirms no change in the substance or decisions of the resolutions passed.
- TTM revenue stands at Rs 71 Cr with a net profit of Rs 8 Cr as per latest available data.
Aptus Pharma has approved a preferential issue of 16,10,100 equity shares to a broad group of 192 investors. The pricing will be determined based on a valuation report, with August 14, 2026, set as the 'Relevant Date' for minimum price calculation. This capital raise follows a strong FY26 performance where revenue grew 89% YoY to ‡46.57 Cr. Shareholders will vote on the proposal at the Annual General Meeting scheduled for September 14, 2026.
- Issuance of 16,10,100 equity shares with a face value of ‡10 each.
- Preferential allotment proposed to a total of 192 distinct investors.
- Relevant Date for pricing fixed as August 14, 2026, 30 days prior to the AGM.
- Annual General Meeting (AGM) to be held on September 14, 2026, for shareholder approval.
- Estimated equity dilution of approximately 8.6% based on the current share capital.
Aptus Pharma has scheduled a board meeting for August 8, 2026, to evaluate a proposal for raising funds through a preferential allotment of equity shares or other securities. This move comes as the company shows strong growth, with TTM revenue reaching ₹71 Cr and a high ROCE of 30.0%. With a current net worth of ₹23 Cr and a manageable debt-to-equity ratio of 0.31, the fresh capital could be used for expansion or working capital. Investors should watch for the quantum of the fundraise and the identity of the allottees to gauge the impact on equity dilution.
- Board meeting scheduled for August 8, 2026, to deliberate on fund raising via preferential allotment.
- Trading window for designated persons closed from August 5, 2026, until 48 hours after the meeting outcome.
- Company reported a significant revenue jump to ₹46.57 Cr in FY26 from ₹24.56 Cr in FY25.
- Current TTM PAT stands at ₹8 Cr with an operating profit margin of 17.3%.
- Promoter holding remains stable at 72.89% as of June 2026.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Products & Services
Pharmaceutical products and medicines (implied by company name), though specific therapeutic categories or formulations are not disclosed in available documents.
External Factors
Industry Trends
The Indian pharmaceutical industry is a global leader in generic drugs, currently experiencing steady growth driven by increased healthcare spending and export demand. The industry is shifting towards more complex formulations and digital manufacturing processes to improve efficiency and compliance.
Competitive Landscape
The pharmaceutical sector is highly competitive with numerous domestic and international players. Competition is based on pricing, product quality, and the ability to navigate complex regulatory environments.
Consumer Behavior
There is a growing consumer preference for branded generics and a rising demand for chronic care medications due to lifestyle changes, which provides a more predictable demand pattern for pharmaceutical companies.
Regulatory & Governance
Industry Regulations
The company must adhere to the Drugs and Cosmetics Act and Good Manufacturing Practices (GMP). Regulatory oversight is intense; any failure to meet quality standards could result in product bans or facility closures, which would halt revenue generation from those lines.
Risk Analysis
Risk analysis not yet available for this company.
